Real World Outcomes with Ide-Cel CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma 

Dr. Surbhi Sidana discusses the largest real-world study that looks at the Ide-Cel CAR T-cell therapy in the relapsed/refractory multiple myeloma population. 

Abstract Title:

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Presented at ASH 2023   

What is the purpose of this trial?  

The primary goal of this study is to assess the safety and efficacy of ide-cel when used as the standard of care for individuals with relapsed/refractory multiple myeloma (RRMM). The trial seeks to understand how ide-cel performs in a diverse group of patients, ensuring that its benefits extend to a broad range of individuals with RRMM. 

In this video: 

Surbhi Sidana, MD, (Stanford University — Stanford, CA) discusses the largest real-world study that looks at the Ide-Cel CAR T-cell therapy in the relapsed/refractory multiple myeloma population. 

Conclusion: 

In the largest study ever done in the real world on ide-cel CAR-T cell therapy for people with RRMM, researchers found that it is safe and works well. Even though many patients had a lot of treatments before, and some had health issues (comorbidities) that might not have qualified them for the KarMMa clinical trial, researchers still saw good results. These findings strengthen the idea that ide-cel can be an effective treatment choice for a wide range of real-world patients dealing with RRMM. 

Trial Information: Abstract #1027 (https://ash.confex.com/ash/2023/webprogram/Paper181762.html) 

Doctor Bio: 

Surbhi Sidana, MD, is a hematologist/oncologist with specialized training in advanced hematology, focusing on myeloma, amyloidosis, and dysproteinemia disorders. Serving as an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy at Stanford University School of Medicine, she leads the Myeloma Cellular Immunotherapy program. 

Her expertise spans transplantation and innovative cellular immunotherapies, notably CAR-T-cell therapy for patients grappling with multiple myeloma. Dr. Sidana is dedicated to crafting individualized care plans for each patient, aiming to optimize outcomes and enhance their quality of life. 

Dr. Sidana spearheads clinical trials exploring the efficacy of CAR-T therapy and bispecific T-cell engagers in treating myeloma patients. Her investigations extend to understanding patients' accessibility to CAR-T cell therapy, the financial implications of treatment, and its effects on quality of life and cognitive function. 

Recipient of a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program, Dr. Sidana is delving into the adverse events of CAR-T therapy on patients and employing wearable devices to monitor those undergoing this transformative treatment. 

She has received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology. Dr. Sidana has also received grants from the Amyloidosis Foundation and International Waldenstrom’s Macroglobulinemia Foundation. Other honors include Outstanding Hematology/Oncology Fellow award and Outstanding Research Fellow award from the Mayo Clinic. She is an active member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and American Society of Transplantation & Cellular Therapy.